Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases

Raffaello Mancini, Manfredo Tedesco, Carlo Garufi, Angelo Filippini, Stefano Arcieri, Mauro Caterino, Giuseppe Pizzi, Enrico Cortesi, Antonella Spila, Isabella Sperduti, Maurizio Cosimelli

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Only 5-10% of colorectal cancer patients (pts) with liver metastases are eligible for surgical resection. Regional and systemic chemotherapy represents the best therapeutic options for unresectable metastases. Materials and Methods: In a randomized phase II trial 123 pts were enrolled with a minimum follow-up of 3 years. In Arm A 58 pts were submitted to intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day, while the other 65 were included in Arm B (bolus of CDDP, 24 mg/m2/day). All the pts were also given i.v. escalating doses of fluorouracil. Response was evaluated after a minimum of 3 cycles. Results: Toxicity ≥G3 was lower in Arm B. The objective response rate was 52% in all the series, the complete responses being 17.3% (17.6% vs. 17% in Arms A and B, respectively). The overall median survival was 18 months rising to 28 months in the responders. Conclusion: CDDP HAI provided similar results as FUdR in terms of response to treatment. Moreover, long-term survivors were unexpectedly observed.

Original languageEnglish
Pages (from-to)1837-1841
Number of pages5
JournalAnticancer Research
Volume23
Issue number2 C
Publication statusPublished - Mar 2003

Keywords

  • Cisplatin
  • Colorectal cancer
  • Liver metastases
  • Regional chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases'. Together they form a unique fingerprint.

Cite this